Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus

AZ and Sanofi’s Antibody Success Against The Often Deadly Infection

 
• By Andrew McConaghie
  
Boy_Inhaler
Respiratory synctial virus (RSV) is one of the biggest causes of hospitalization and death in infants worldwide.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip